Trial Profile
Evaluation of predictive markers of glitazone efficacy in diabetic patients - pilot study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Therapeutic Use
- 08 Jul 2019 Status changed from completed to withdrawn prior to enrolment.
- 28 Jan 2009 Planned patient numbers amended from 30 to 12 as reported by ClinicalTrials.gov.
- 28 Jan 2009 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.